Cell cycle regulation of deoxycytidine kinase Evidence for post-transcriptional control by Hengstschläger, Markus et al.
Volume 321, number 2,3, 237-240 FEBS 12358 
0 1993 Federation of European Biochemical Societies 00145793/93/$6.00 
April 1993 
Cell cycle regulation of deoxycytidine kinase 
Evidence for post-transcriptional control 
Markus Hengstschllger, Claudia Denk and Edgar Wawra 
Vienna Biocenter, Institute for Molecular Biology, Dr. Bohrgasse 9, A-1030 Vienna, Austria 
Received 15 February 
Deoxycytidine kinase enzyme activity and deoxycitidine kinase mRNA content were determined at different positions of the cell cycle in permanent 
cell lines. There was no variation of deoxycytidine kinase activity during the cell cycle in two cell lines, whereas in two other lines the enzyme activity 
was induced (IO- and 15-fold) at the GUS boundary. In contrast, the level of deoxycytidine kinase mRNA never displayed any cell cycle-dependent 
changes. The decay of enzymatic activity was measured after addition of cycloheximide in different phases of the cell cycle; the enzyme was much 
more stable in cells with constant activity. We suggest hat post-transcriptional mechanisms account for the periodic behaviour of the enzyme 
activity, and that whether this regulation can be detected epends on the half-life of deoxycytidine kinase. 
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1. INTRODUCTION 
Deoxycytidine kinase (dCK; EC 2.7.1.74) catalyzes 
the phosphorylation of deoxycytidine to deoxycytidine 
5’-monophosphate using triphosphates as phosphate 
donors. This enzyme has a broad substrate specificity 
[ 1,2] and plays a physiologic role in the maintenance of 
normal deoxyribonucleotide pools. It is responsible for 
the initial activation of a number of clinically important 
chemotherapeutic and antiviral agents, such as ~-/I-D- 
arabinofuranosylcytosine (Ara-C), 2-fluoro-9-/?-n-ara- 
binofuranosyladenine, and 2’,3’-dideoxycytidine [3,4]; 
deficiency of dCK activity causes resistance to these 
drugs. 
The cDNA for this enzyme has been cloned and the 
corresponding amino acid sequence of the protein sub- 
sequently predicted [5]. Very recently the structure and 
chromosomal ocalization of the human dCK gene has 
been published [6], which is the basis for obtaining fur- 
ther insight into the regulation of its expression. 
In eukaryotic cells deoxyribonucleoside triphosphate 
biosynthesis occurs periodically in close relation with 
DNA replication. Enzymes responsible for the biosyn- 
thesis of deoxyribonucleotides, uch as ribonucleotide 
reductase, thymidylate synthetase, deoxycytidine deam- 
inase, uridine kinase, dihydrofolate reductase, and thy- 
midine kinase, are essentially synthesized during S 
phase of the cell cycle (reviewed in [7]). Although the 
salvage pathway enzyme dCK also belongs to this 
Correspondence address: M. Hengstschllger, Vienna Biocenter, Insti- 
tute for Molecular Biology, Dr. Bohrgasse 9, A-1030 Vienna, Austria. 
Fax: (43) (1) 7951 2901. 
group of enzymes, its activity was believed to be much 
less influenced by progression through the cell cycle 
phase. Earlier studies of Pregoraro and Bernengo [8] 
and Arner et al. [9] demonstrated a high dCK activity 
(- 30 pmol/mg/min) in resting lymphocytes and a mod- 
est (2- to 3-fold) increase of activity after phytohemag- 
glutinin stimulation. Very similar observations were 
made after serum stimulation of BHK21/C13 cells; 
whereas thymidine kinase activity increased 20-fold 
from a very low initial level after stimulation, dCK ac- 
tivity remained at a constant high level [lo]. In addition, 
Richel et al. [l l] could not detect any variation of dCK 
activity during the cell cycle of elutriated HL-60 cells. 
Recently it has been demonstrated [5,6] that the 
steady state level of dCK mRNA varies in different cell 
types. For more detailed characterization of the regula- 
tion of dCK expression, we studied enzyme activity and 
mRNA levels during the cell cycle of various permanent 
cell lines. This work presents evidence for post-tran- 
scriptional regulation of deoxycytidine kinase expres- 
sion during the eucaryotic cell cycle. 
2. MATERIALS AND METHODS 
2.1. Cells 
3T6 cells (permanent line of contact inhibited mouse fibroblasts; 
ATCC CCL96) and COP-8 cells (polyoma transformed mouse cells) 
were grown on plastic Petri dishes in Dulbecco’s modified Eagles’s 
(DME) medium supplemented with 10% calf serum. HeLa cells 
(human cervix carcinoma; papilloma transformed eels; ATTC CCLZ) 
and Epstein Barr virus-transformed human lymphocytes (EBV lymph) 
were cultivated in 75-cm’ flasks containing RPM1 medium with 10% 
calf serum. All tissue cultures were maintained at 37’C and 5% CO,, 
and were routinely screened for the absence of mycoplasma. 
Cells were fractionated with a JE-6B Elutriator in a J2-21M centri- 
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fuge (Beckman) as previously described [12]. Medium flow was con- 
trolled with a Cole-Parmer Masterflex pump and the rotor was kept 
at a speed of 2,000 rpm. The elutriation~ medium was phosphate- 
buffered saline (PBS) supplemented with 0.9 mmol/l CaCl,, 0.5 mmol/l 
MgCl, and 2% calf serum. Each elutriated fraction was monitored by 
a PAS-II flow cytometer (Partec) using 6 PmoVl 4,6-diamidino-2- 
phenylindol-dihydrochlorid (DAPI) (Merck) to stain DNA. 
2.2. Deoxycytidine kinase assay 
Samples were diluted in the sample buffer as described [131 and the 
protein concentration in these extracts were measured by the method 
of Bradford [ 141 using the Bio-Rad protein assay reagent with bovine 
serum albumin as a standard. Enzyme activity was determined by a 
method described by Ives and Wang [ 131. dCK activity was measured 
with [5-3H]deoxycytidine (0.5 PCi; spec. act. 25.6 Ci/mmol) as sub- 
strate in a reaction mixture containing 50 mM Tris-HCl (pH 7.6), 5 
mM MgCl,, 5 mM ATP, 2 mM DTT, 10 mM NaF and about 0.5 
mg/ml of cell extract. Samples were incubated at 37”C, 15 ~1 were 
spotted on DEAE cellulose filters which were washed and counted. 
2.3. RNA extractions and Northern blotting 
RNA was isolated after cell lysis in an isotonic buffer containing the 
nonionic detergent NP40 and after removal of nuclei by centrifugation 
[ 151.20 pg of each sample was electrophoresed in a 1% formaldehyde 
agarose gel. RNA was transferred to a nylon membrane, hybridized 
sequentially with 32P-radiolabeled probes specific for dCK and 82- 
microglobulin sequences, and the ratio determined by densitometry. 
2.4. dCK cDNA probe 
We synthesized a23mer sense oligonucleotide (position 734-756 bp 
of the dCK cDNA) and a 22mer antisense oligonucleotide (position 
1422-1443 bp), both homologous to the dCK cDNA published by 
Chottiner et al. [5]. Using these oligonucleotides as primers for the 
polymerase chain reaction, templated by cytoplasmic RNA of the cell 
line MOLT-4 (ATTC CRL1582), we amplified a 710 bp cDNA frag- 
ment, which could be identified as dCK-specific by two HindDIII 
cleavage sites. Hybridization with this probe revealed a single 2.8 kb 
mRNA as described for dCK [5]. 
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Fig. 1. dCK activity vs. mRNA content during the cell cycle of 
elutriated 3T6 mouse fibroblasts. Cells were separated into fractions 
of different cell cycle position by centrifugal elutriation as indicated 
at the top (Gl, S and G2). (a) DNA content was quantitated by flow 
cytometry after staining with DAPI. (b) dCK activity is given in pmol 
dCMP formed/mg protein/hour. (c) dCK mRNA is normalized to 
/32-microglobulm and expressed in relative units (the highest value = 
100%. 
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Fig. 2. dCK activity vs. mRNA content during the cell cycle of 
elutriated Epstein Barr virus-transformed lymphocytes. (a) DNA con- 
tent. (b) dCK enzyme activity. (c) dCK mRNA level. See Fig. 1 for 
more detailed information. 
3. RESULTS 
3.1. dCK enzyme activity during the cell cycle 
Four permanent lines were separated according to 
their phase of the cell cycle by centrifugal elutriation. 
During the elutriations of HeLa cells and EBV-trans- 
formed lymphocytes the medium flow rates were 
changed in larger steps. The cell cycle of these cells were 
divided in only six fractions (compared to nine and ten 
in COP-8 and 3T6) to be sure to get enough cells per 
fraction for the analyses of dCK activity and mRNA 
level. 
As the DNA distribution of the collected fractions 
indicate, the separation quality of all four elutriations 
shown in Figs. l-4 was comparable. The first fraction 
reflects a distribution of about 88% Gl-, 10% S- and 2% 
G2/M-cells. The best S-phase fractions derived from 
each of the four cell lines also had comparable amounts 
of cells of different cell cycle position (17% Gl, 70% S, 
13% G2/M). Only the G2/M fractions of COP-8 cells 
contained a higher amount of Cl and S phase cells than 
the other cell lines. The average distribution of the best 
G2/M fractions of 3T6 mouse fibroblasts, HeLa cells 
and EBV transformed lymphocytes was 8% Gl, 15% S 
and 77% G2/M. 
3T6 mouse fibroblasts and human EBV-transformed 
lymphocytes do not display any cell cycle regulation of 
dCK enzyme activity (see Fig. lb and Fig. 2b). In both 
cell lines the activity only varies between 50 and 100 
pmol dCMP formed/mg protein/min during the cell 
cycle. This is in agreement with the measured dCK ac- 
tivities in logarithmically growing 3T6 cells and virus 
transformed lymphocytes (see Table I). 
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Fig. 3. dCK activity vs. mRNA content during the cell cycle of the 
permanent cell line COP-8 (polyoma-transformed mouse fibroblasts). 
(a) DNA content. (b) dCK enzyme activity. (c) dCK mRNA level. See 
Fig. 1 for more detailed information. 
In Gl cells of HeLa and COP-8 the dCK activity is 
very low. A lo- and 15fold induction of dCK activity 
appeared at the Gl/S boundary of the cell cycle of these 
cells. During the G2 phase of these two lines the activity 
slightly decreased, but mainly kept the elevated level. 
This Gl/S induction to a high dCK activity in S and G2 
could be an explanation for the high enzyme activity in 
logarithmically growing cells (compare Table I). 
3.2. dCK mRNA level during the cell cycle 
We also determined the dCK mRNA level in each 
separated fraction. The obtained values were normal- 
ized to /?2microglobulin mRNA, which is well known 
to be constitutively expressed. As seen in Figs. 14c, no 
cell cycle regulation of dCK mRNA could be detected. 
The mRNA level of this enzyme increased during the 
cell cycle of COP-8 cells. As this induction is less than 
1.5-fold, it does not indicate a cell cycle regulation. 
3.3. dCK enzyme stability 
After centrifugal elutriation separated Gl , S and G21 
M cells were recultivated in the presence of cyclo- 
heximide. 0, 1.5, 3, 4.5 and 6 h after recultivation dCK 
activity was measured and the half-life of enzyme activ- 
ity in the different cell cycle phases was determined 
(Table I). In no studied lines was cell cycle-dependent 
variation of the dCK stability detected. In 3T6 mouse 
fibroblasts and in EBV-transformed lymphocytes, the 
enzyme is constitutively more stable (3- to 4-fold) than 
in COP-8 and HeLa cells. Interestingly, the average of 
enzyme activity in logarithmically growing cells was 
2-fold higher in HeLa cells and COP-8 cells than in 3T6 
cells and transformed lymphocytes. 
4. DISCUSSION 
As deoxyribonucleoside triphosphate biosynthesis is 
closely connected with DNA replication, the enzymes 
responsible for this replication are mainly expressed 
during the S phase of the eucaryotic cell cycle [7]. The 
salvage pathway enzyme deoxycytidine kinase also be- 
longs to DNA precursor pathway enzymes, but its ac- 
tivity was shown to be cell cycle independent [8-111. 
We suggest hat it depends on the cell type, whether 
dCK activity increases during S phase or not. In the two 
permanent cell lines COP-8 (polyoma-transformed 
mouse cells) and HeLa (human cervix carcinoma; papil- 
loma-transformed) a lo- and 15-fold induction at the 
Gl/S boundary was detected. In contrast 3T6 mouse 
fibroblasts and human Epstein Barr virus (EBV) trans- 
formed lymphocytes do not display any cell cycle regu- 
lation of dCK activity. Interestingly, cell cycle-depend- 
ent variations of the steady-state mRNA level could not 
be detected. This fact suggests a post-transcriptional 
control of dCK expression during the cell cycle. When 
measured in the presence of cycloheximide, the enzyme 
is much more stable in the non-regulated cells compared 
to the regulated cases. It seems that the post-transcrip- 
tional regulation of dCK observed in COP-8 and HeLa 
cells cannot be determined in 3T6 cells or EBV trans- 
formed lymphocytes, because of the longer half-life of 
the enzyme. Once an antibody for dCK is available it 
would be interesting to determine the half-life of the 
protein during the eucaryotic cell cycle. 
Sherley and Kelly [ 161 defined the molecular basis for 
the periodic expression of thymidine kinase activity dur- 
ing the eucaryotic cell cycle. Studying HeLa cells they 
showed that the large induction of thymidine kinase 
activity on the Gl/S boundary is not paralleled at the 
Table I 
Half-life of dCK enzyme activity in different cell cycle phases in the 
presence of cycloheximide and dCK activities in logarithmically grow- 
ing cells 
Cell line Half-life of dCK enzyme dCK activity 
activity in hours in logarithmi- 
cally growing 
Gl S G2lM C&4* 
EBV lymph 13.1 f 1.2 12.8 f 0.8 11.6 f 1.7 82.3 f 11.8 
3T6 11.2 + 1.4 9.8 zk 2.3 10.9 * 2.2 74.5 + 23.5 
COP-8 2.5 f 0.9 3.2 f 1.4 2.8 + 1.4 153.4 f 33.9 
HeLa 2.2 + 1.1 2.8 f 2.0 3.5 zh 0.5 149.6 f 19.1 
Cells were separated by centrifugal elutriation according to their size. 
Fractions representative for Gl, S, or G2 phase of the cell cycle were 
re-cultivated in the presence of 10 @ml cycloheximide, At 0, 1.5, 3, 
4.5, and 6 h after recultivation, dCK activities were measured. Half- 
lifes of dCK activity in the different cell cycle phases were determined. 
Values are means of three independent measurements f S.D. 
*The dCK activities in logarithmically growing cells are given in pmol 
dCMP formed/mg protein/mm. (EBV lymph, Epstein Barr virus- 
transformed human lymphocytes). 
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Fig. 4. dCK activity vs. dCK mRNA content during the cell cycle 
of elutriated HeLa cells. (a) DNA content. (b) dCK enzyme activity. 
(c) dCK mRNA level. See Fig. 1 for more detailed information. 
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mRNA level. The authors postulated a lo-fold greater 
efficiency of translation of thymidine kinase mRNA 
when cells begin DNA replication. In addition, the sta- 
bility of thymidine kinase protein dramatically de- 
creased upon cell division. 
Studying deoxycytidine kinase activity and mRNA in 
HeLa cells and in polyoma-transformed mouse cells 
(COP-Q revealed a comparable regulation. Whereas the 
steady-state mRNA level is not cell cycle-regulated, the 
dCK enzyme activity is induced lo- and 15fold at the 
Gl/S boundary. In this work we show that the dCK 
enzyme stability does not vary between Gl-, S- and 
G2/M-phase of these two cell lines. However, we do not 
know if there exists an increased protease activity de- 
grading deoxycytidine kinase during metaphase of mi- 
tosis, as is postulated for thymidine kinase [17]. One 
may speculate that a dramatically decreased stability 
during mitosis, as described for thymidine kinase, could 
lead to the observed very low dCK activity in Gl phase 
of HeLa and COP-8 cells. 
Our data indicate that this difference in dCK enzyme 
stability seems not to be a marker for transformation, 
as EBV-transformed lymphocytes and HeLa cells (cer- 
vix carcinoma; papilloma-transformed) isplay a totally 
different dCK stability. It would be interesting to look 
for a correlation between a specific kind of transforma- 
tion and the observed changes of dCK regulation. Cer- 
tainly we showed that the variation in dCK stability is 
not a difference between mice and man. 
Several studies have demonstrated that dCK is ex- 
pressed at variable levels in different tissues. The activ- 
ity of this enzyme in leukemic T lymphoblasts and in 
thymus glands has been shown to be higher than in 
other cell types (reviewed in [6]). Maybe the two ob- 
served dCK enzyme stabilities play an additional role 
in these different levels of expression. 
Because of the potential role for this enzyme in medi- 
ating the tissue-specific ytotoxicity of chemotherapeu- 
tic agents, further characterization of the factors regu- 
lating dCK expression should be done. An important 
question to answer (e.g.) would be: is the observed dif- 
ference in enzyme stability specific for dCK or are other 
DNA precursor pathway enzymes similarly affected? 
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